Associates
James Frost
James Frost’s M.D., Ph.D. (nuclear and radiochemistry) degrees are from Washington University; an M.B.A. from Johns Hopkins University, completing Diagnostic radiology and nuclear medicine residencies there, becoming board certified in both specialties. With a university clinical practice since 1982, he is also a clinical trials reader.
He was on the Johns Hopkins’ team that accomplished the first imaging of a neuroreceptor and led the group that first imaged the brain opioid receptor in 1983. In 15 years on Johns Hopkins Institutional Review Board. he saw human investigation protocols spanning all areas of medical research and was Chairman of the Radioactive Drug Research Committee and Clinical Radiation Research Committee, reviewing all studies involving ionizing radiation.
Dr. Frost designed Yale University PET Center, creating a 10-year financial and strategic plan for molecular imaging research across multiple University departments, co managing a 10-year bioimaging alliance with Pfizer. Director of the PET Center, he was responsible for 25 staff, acquisition of $8M in equipment, including cyclotron, PET scanner, and chemistry laboratory, and Medical Director and Authorized User for ionizing radiation, Section Chief for Nuclear Medicine’s clinical PET-CT imaging and general clinical nuclear medicine studies. Currently President of Biomarking and Molecular Imaging Solutions, LLC, Dr. Frost is an Executive in Residence at BlueTree Capital in Pittsburgh, PA, evaluating companies for investment and. consulting for venture capital funds to determine how in vivo molecular imaging can be used to understand properties of early stage drug candidates. He is also a board member of DiaKine Therapeutics.